Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.

@article{Isaac2002ConcurrentCM,
  title={Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.},
  author={Neil Isaac and Tony Panzarella and Anthea Lau and Catherine Mayers and Peter Kirkbride and Ian F. Tannock and Katherine Anne Vallis},
  journal={Cancer},
  year={2002},
  volume={95 4},
  pages={696-703}
}
BACKGROUND The current study was conducted to assess the toxicity of concurrent adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy (RT) for early breast carcinoma. METHODS In the current study, the authors reviewed the records of 680 consecutive breast carcinoma patients who received adjuvant CMF at the Princess Margaret Hospital between 1980-1990. Surgery was comprised of mastectomy in 64% of patients, breast conservation in 35% of patients, and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Main controversies in breast cancer.

World journal of clinical oncology • 2014

Radiochemotherapy in the treatment of breast cancer.

Clinical oncology (Royal College of Radiologists (Great Britain)) • 2009

Similar Papers

Loading similar papers…